Cannabis mergers have run aground since the tide went out on pot stocks. Earlier this month, MedMen Enterprises killed its $680 million deal with PharmaCann. A Tuesday press release by Cresco Labs proclaimed the completion of antitrust review for its $800 million merger with Origin House. But it went on to say the companies need to negotiate the terms of the deal they’d announced in April, when cannabis stocks were at their peak.
The April deal had arranged for the exchange of 0.8428 of a Cresco share for each share of Origin…
Recent Comments